Literature DB >> 27408381

A Case Presenting with Splenic Infarct Diagnosed as Primary Bone Marrow CD5 Positive DLBCL: A Clinicopathological Correlation.

Anupriya Bansal1, Suchi Mittal1, Jasmita Dass1, Nitin Gupta2, P K Agarwal3, Jyoti Kotwal1.   

Abstract

De novo CD5+ Diffuse large B cell lymphoma (DLBCL) is a rare and aggressive subtype of DLBCL. It is a distinct clinicopathologic entity with complex molecular profile and poor prognosis. A 59 year old female presented with pyrexia of unknown origin since 1 month. On examination, there was severe pallor, hepatosplenomegaly and no palpable lymphadenopathy. Complete blood count revealed bicytopenia with normal total leucocyte count. Liver and renal function tests were normal. Ultrasonography abdomen revealed splenic enlargement with two focal lesions attributed to either splenic abscess or infarcts. Patient was being managed as splenic infarct but continued to have bicytopenia. Further investigation showed elevated serum ferritin, triglycerides and LDH. With a clinical suspicion of infection and haemophagocytic lymphohistiocytosis bone marrow aspiration (BMA) and biopsy (BMBx) was done. BMA showed extensive haemophagocytosis and ~7.4 % large lymphoma-like cells. On this basis PET-CT was suggested which showed enlarged spleen with diffuse uptake. BMBx showed nodular and intrasinusoidal collection of abnormal lymphoid cells. On immunohistochemistry, these cells were positive for CD20, CD5, MUM1, BCL-2, BCL-6 and negative for CD3, CD10 and CD23. CD34 highlighted focal intrasinusoidal pattern. The complete clinicopathological profile suggested the diagnosis of de novo CD5+ DLBCL, with primary hepatosplenic pattern of involvement. CD5+ DLBCL presenting as splenic infarct is very rare. This case was unusual as the diagnosis of a primary aggressive lymphoma with haemophagocytosis was established in a patient who presented with fever and splenic infarct without lymphadenopathy. This indicates the importance of good morphological assessment of a bone marrow aspirate and biopsy to make a correct diagnosis.

Entities:  

Keywords:  DLBCL; De novo CD5+; Hemophagocytosis; Hepatosplenic; Splenic infarct

Year:  2016        PMID: 27408381      PMCID: PMC4925553          DOI: 10.1007/s12288-016-0646-2

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  10 in total

1.  Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes.

Authors:  S Harada; R Suzuki; K Uehira; Y Yatabe; Y Kagami; M Ogura; H Suzuki; A Oyama; Y Kodera; R Ueda; Y Morishima; S Nakamura; M Seto
Journal:  Leukemia       Date:  1999-09       Impact factor: 11.528

2.  De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.

Authors:  Motoko Yamaguchi; Masao Seto; Masataka Okamoto; Ryo Ichinohasama; Naoya Nakamura; Tadashi Yoshino; Junji Suzumiya; Takuhei Murase; Ikuo Miura; Takashi Akasaka; Jun-ichi Tamaru; Ritsuro Suzuki; Yoshitoyo Kagami; Masami Hirano; Yasuo Morishima; Ryuzo Ueda; Hiroshi Shiku; Shigeo Nakamura
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm.

Authors:  Martine Szyper-Kravitz
Journal:  Isr Med Assoc J       Date:  2009-10       Impact factor: 0.892

Review 4.  How I treat hemophagocytic lymphohistiocytosis.

Authors:  Michael B Jordan; Carl E Allen; Sheila Weitzman; Alexandra H Filipovich; Kenneth L McClain
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

5.  Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.

Authors:  N Niitsu; M Okamoto; J-i Tamaru; T Yoshino; N Nakamura; S Nakamura; K Ohshima; H Nakamine; M Hirano
Journal:  Ann Oncol       Date:  2010-03-15       Impact factor: 32.976

6.  Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5.

Authors:  Takuhei Murase; Motoko Yamaguchi; Ritsuro Suzuki; Masataka Okamoto; Yumiko Sato; Jun-ichi Tamaru; Masaru Kojima; Ikuo Miura; Naoyoshi Mori; Tadashi Yoshino; Shigeo Nakamura
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

7.  Clinical characteristics of B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS): comparison of CD5+ with CD5- B-LAHS.

Authors:  C Shimazaki; T Inaba; A Okano; M Hatsuse; R Takahashi; H Hirai; Y Sudo; E Ashihara; Y Adachi; S Murakami; K Saigo; H Tsuda; N Fujita; M Nakagawa
Journal:  Intern Med       Date:  2001-09       Impact factor: 1.271

Review 8.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors:  Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

9.  B-cell lymphomas with coexpression of CD5 and CD10.

Authors:  Henry Y Dong; Wojciech Gorczyca; Zach Liu; Patricia Tsang; C Daniel Wu; Patti Cohen; James Weisberger
Journal:  Am J Clin Pathol       Date:  2003-02       Impact factor: 2.493

10.  CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse.

Authors:  J A Ferry; W I Yang; L R Zukerberg; A C Wotherspoon; A Arnold; N L Harris
Journal:  Am J Clin Pathol       Date:  1996-01       Impact factor: 2.493

  10 in total
  1 in total

1.  A Case of Primary Bone Marrow Diffuse Large B-cell Lymphoma Presenting With Fibrillar Projections and Hemophagocytic Lymphohistiocytosis.

Authors:  Min Sun Kim; Young Uk Cho; Seongsoo Jang; Eul Ju Seo; Jung Hee Lee; Chan Jeoung Park
Journal:  Ann Lab Med       Date:  2017-11       Impact factor: 3.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.